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1959-49]AreACTsHelpfulintheManagementof
Anticoagulation With Low Molecular Weight
Heparin?
T.D. Henry, L.L. Knox, C.L. Iacerella, D.D. Laxson. f-fennepirrCounty
Medical CenteL Minneapolis, MN, USA, University of Minnesota,
Minneapolis, MN, USA
Enoxaparin (Enox) has been approved for prophylaxis for venous throm-
boambolism”and has shown promise in unstable angina and post corona~
stent placement. The ratio of anti-Xa:anti-lla activity for Enox (3:1) is higher
than with heparin (1:1). Both aPTT and activated clotting time (ACT).are
used to monitor anticoagulation with heparin. ACTSare now standard for
monitoring anticoagulation during acute coronary intenfention. At doses up
to 90 mg, SQ Enox doas not prolong the aPTT but ‘the effect on ACT is
unknown. TIMI Ila was a multicanter dose-ranging trial (1.0-1 .25 mg/kg SQ
q12 hre) to evaluate the aafety and tolerability of Enox in patients with unsta-
ble anginalnon-Q wave Ml. We obtained peak (mean 4.3 hrs post-Enox) and
trough (mean 11.5 hrs post-Enox) anti-Xa levels and ACTSfor 26 patients in
the TIMl 11a trial as shown below. Despite large doses of Enox (89 + 19 mg
q12 hra) and significant increases in anti-Xa levels even at the trough, there
waa no change in ACT measured by Hemotec and only a small increase
with Hemachron. In addition, the correlation of peak Hemachron ACT with
peak anti-Xa levels was poor (R= 0.5, P = 0.0S). Conckrsion: In contrast to
heperin, ACTsare not adequate for assessment of antimagulation with Enox.
Therefore, ACTSshould not be relied upon in patients on Enox who require
acute coronary intervention or additional anticoagulation with heparin.
n Trough Peak Normals
n (No Anticoagulation)
Hemotec ACT 15 127+ 21 127 & 9 127+ 16
HemachronACT 11 136+ 19 152 + 28* 126+ 25
TotalACT 26 131 +20 138+ 23
Anti-Xa 26 0.51 * 0.28 1,3+0.40” 0,0
8“ data: msan & SD. *p <0.05 vs. normal, ** p <0.0001 vs. trough
1959-501DOf~tilideDeCreaSaDefibriilationThreahold,BUt
not in Proportion to its Prolongation of
Refractoriness and QT Intervala
J. Huang, B.H. KenKnight, W.M. Smith, R.E. Ideker. University of A/abarna
at Birmingham, AL, USA
We tested the hypothesis that dofetilide causes a reduction in defibrillation
threshold (DFT) that ia inversely proportional to the changes it causes in the
effective refractory period (ERP) and QT intervals. In 12 pigs, two platinum
spring electrodes were placed in the RV apex and the RV-SVCjunction. Six
pigs were studied using three cumulative doses of dofetilide (2.5, 7.5 and 15
!.@k9 bOkIS+0.9, 3.6 and 9 @kg/hr maintenance, respectively). Six control
piga were given saline. DFTswere determined uaing an up/down protocol by
giving fixed-duration (10 ins), single capacitor (150 uF) biphasic shocks (6
ms phase 1). LV-ERPmeasurement were made with endocardial stimuli and
QT intervals were obtained from surface ECG lead Il. Ventricular fibrillation
cycle lengths (VF cl) were measured from LV endocardial electrograms. “p
<0.05 vs Baseline.
Dofetilide Doaa (p@g) D~ (V) ERP (ins) QTc (ins) VF cl (ins)
Sasaline O 373 &81 185 + 16 430+21 88+ 7
Low 2.5 337 & 80” 210 * 14 450 *21 98+ tl”
Mid 7,5 349 l54 218 + 14” 459 & 12* 107 l 13*
High 15 366 * S7 242 + 39* 465 h 30 110 + 18”
There was no significantly difference for the aboveparameter in the
controlgroup.
Cone/usiorr:DofetilidesignificantlyreducesDFToniyinitslowdoseinpigs
andtheeffectonDFTisnotmonotonicallyrelatedto itseffectof prolongation
ofERPandQTintervals.Thus:(1)onlyasmallDFT effect of dofetilideoccurs
in pigs, which differs from dogs studied by others and (2) the dacreaaa in
DFT is not related in a 1:1mannerwithincreasain ERP.
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~960-109] Deficiency of Cell Adhesion Molecules Protects
Against Atherosclerosis in Mice
M.F. Nageh 1, E.T,Sandberg 1, K.R. Marotti 2, A,H. Lin 2, E.P. Melchiorz,
D.C, Bullard AL. Beaudet 1.1 Bay/or Co//ege of Medicirre, Houston, TX,
USA, 2Pharmacia & Upjohn Inc., Kalamazoo, Ml, USA
Leukocyte and endothelial cell adhesion molecules (CAM) are essential for
emigration of leukocytes. Based on the evidence for an increaaed expression
of CAM in atherosclerotic lesions, we testad the hypothesis that reduced
expression of CAM might be protective againat the disease. Uaing C57BIJ6
female mice which develop atherosclerotic fatty streaks on high fat diet,
animala which were homozygous or wild type for the CAM mutation were
atartadon high fat diet attheage of 12weeks, and atter20weeka on diet, they
were sacrificed, Hearts were removed and fixed, and atherosclerotic Iesiona
quantified using standard methods. Compared to wild type, the reduction in
the lesions was as follows: 47% for the CD18 deficient mice, (P < 0,03),
63% reduction for the ICAM-1 deficient mice (P < 0.0003), 63% for the P-
selectin deficient mice (P < 0.0001), 76% for the combined CDIWICAM-1
deficient mice (P < 0.0001), and 71% for the combined ICAM-1/P-selectin
group (P < 0.0002). Lipid analyais revealed significant differences only in
the P-selectin groups, which had higher HDL levels than the control group,
The above data provide the strongest evidence to date for a direct cause
and effect role for CAM in the development of atherosclerosis, and auggasts
that genetic variation in CAM could affect susceptibility to the diseaae, and
that pharmacologic reduction in the expression or function of CAM might be
protective againat atherosclerosis.
m960108 ExpressionofAdheaionMoleculeaonMicrovesselsinAdvancedHumeriAtherosclerotic
Plaques:AltarnativePathwaysfor Leukocyte
Recruitment
O.J. de Boer,A.C. van der Wal, C.M. van der Loos, A.E. Becker. Academic
Medical Center, University of Amsterdam, Amsterdam, The Netherlands
The presence of activated macrophages and lymphocytes is a charaeteria-
tic feature of atherosclerotic (AS) plaques. T cells migrate into the lesiona
after specific interactions with adhesion molecules expressed by endothelial
cells (EC) and leukocytes. Up till now, most studies on the expression of
adhesion moleculas focused on arterial EC, but advanced AS Iesiona have
regions with neovascularised areas (microvessels), and in these areas often
large infiltrate with immunocompetent cella can be found. Recently, a novel
endothelial activation marker was described: CD40, member of the tumor
necrosis factor receptor family of adhesion receptors. Cytokines are capable
to upregulate CD40 on EC. Aftar ligation with its Iigand, CD40 increases the
expression of other adheaion molecules such as VCAM-I and E-selactin,
and, therafore, may play a regulato~ role in the recruitment of immuno-
competent cells in AS Iaaions. In this study, we examined the expression
of CD40, VCAM-1, E-aelectin and ICAM-I on microvascular EC in human
carotid endarteractomy apecimens (n = S) using immunohistochemicei sin-
gle and double staining techniques. We found that all microvessels in human
AS plaques are ICAM-I positive, and focally EC also express VCAM-I and
E-aelectim Focal expression of CD40 was observed on subpcrpdations of
microvaacular EC. Not all activated vessels (VCAM-l+, E-aelectin+) were
CD40 positive, as demonstrated with immunohistochemical double staining
techniques. Thia study shows that microvascular EC are Iikelyto be involved
in the recruitment of immunocompetent cells in AS lesions.
I96O-11OI Temporal and SpetielVariation htAlphavBete3
Integrin Expression Following Deep Arterial Injury
in the Porcine Coronary Reetenosis Model
S.S.Srivatsa, P.Taao,D.R. Holmes, Jr., R.S. Schwartz, S.A. Mousa. Mayo
Clinic, Rochester, MAI,USA, DuPont Merck Pharmaceuticalsr Wilmington,
DE, USA
Background: Cell-matrix interaction via integrin av93-ligand (osteopontin, vif-
ronectin) interaction has been shown to mediate the adhesion and migration
of smooth muscle cells (SfvfC)and endothelial (EC) cells in vitro. Lesa is
known about the ip-vivo expression of LY.B3in vascular restenoaia. Meth-
ods: Using a mouse monoclinal antibody to W?3 (LM609) we atudied its
expression at serial time points following oversized coronary arterial stent
